ArticleBMC surgery2026
Diagnostic confirmation of adult sinonasal rhabdomyosarcoma through comprehensive immunohistochemical profiling: a case report.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdult sinonasal rhabdomyosarcoma (RMS) is an exceptionally rare and aggressive malignancy originating from mesenchymal cells. It poses a significant diagnostic challenge due to its morphological and immunohistochemical overlap with other small round blue cell tumors, such as neuroendocrine carcinoma and olfactory neuroblastoma. Accurate diagnosis requires a high index of suspicion, advanced imaging, and comprehensive histopathology aided with immunohistochemistry (IHC) for specific myogenic markers like Myogenin and MyoD1. CASE PRESENTATION: A 27-year-old male presented with recurrent epistaxis and headache. MRI revealed an enhancing ethmoidal mass with intracranial extension. Following endoscopic surgery, initial pathology suggested neuroendocrine carcinoma. However, a detailed IHC panel showed strong nuclear positivity for MyoD1 and myogenin, confirming RMS. The tumor had a high Ki-67 index (~ 70%). FISH testing was negative for FOXO1 rearrangement, favoring embryonal subtype. Postoperative imaging confirmed complete resection. The patient received adjuvant chemotherapy and radiotherapy.
conclusionThis case underscores the diagnostic difficulty of sinonasal RMS. A definitive diagnosis is contingent upon integrating imaging findings with histopathology and an extensive IHC panel to identify myogenic differentiation. Once confirmed, prompt, multimodal therapy administered through a specialized multidisciplinary center is critical for managing this aggressive neoplasm and optimizing patient outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.